Nektar Therapeutics
NKTR
NKTR
201 hedge funds and large institutions have $3.44B invested in Nektar Therapeutics in 2017 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 73 increasing their positions, 70 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
201
Holders Change
+2
Holders Change %
+1.01%
% of All Funds
5.01%
Holding in Top 10
7
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+600%
% of All Funds
0.17%
New
33
Increased
73
Reduced
70
Closed
24
Calls
$32.8M
Puts
$13.4M
Net Calls
+$19.4M
Net Calls Change
+$17.6M
Top Buyers
| 1 |
BlackRock
New York
|
+$470M |
| 2 |
JPMorgan Chase & Co
New York
|
+$38.1M |
| 3 |
DFO
Duquesne Family Office
New York
|
+$15.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.6M |
Top Sellers
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$29.4M |
| 2 |
BM
Bridger Management
New York
|
-$23.6M |
| 3 |
O
OppenheimerFunds
New York
|
-$23.4M |
| 4 |
Two Sigma Investments
New York
|
-$16.9M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$14.1M |
